Sitagliptin is an oral dipeptidyl peptidase 4 (DPP-4) inhibitor, used to treat type II diabetes, and studies have suggested that the SARS-CoV-2 virus may interact with DPP-4 when entering cells [156]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.